Pep:Trans Peptide Vectors - A New Approach to Brain Delivery

many neurodegenerative diseases – such as stroke, Alzheimer’s disease, and Parkinson’s disease – will become more prevalent. This, together with cancer, infections and a broad range of psychophysical and pain conditions are putting increasing pressure on pharmaceutical companies to produce more effective drugs for brain disorders. Although new neuropharmaceutical drugs are being developed, treatment is often complicated by the inability of these drugs to access their site of action because of the blood brain barrier (BBB). It is estimated that this barrier prevents more than 98% of systemically delivered potential therapeutic drugs from entering the brain. Many novel drugs are under development, but to exploit fully these new therapeutic approaches, there is a compelling need for drug developers to find improved ways of overcoming the blood brain barrier.